In Focus: Stellest trial shows continued efficacy

Results of a clinical trial published in Jama Ophthalmology found Essilor’s Stellest lenses continued to demonstrate strong myopia control efficacy after two years.

Children in the trial were randomly assigned to receive single vision ophthalmic lenses, spectacle lenses with slightly aspherical lenslets (Sal), or Stellest, which was designed based on highly aspherical lenslets (Hal).

The study found higher lenslet asphericity led to higher myopia control efficacy and were more effective at slowing down myopia progression than Sal lenses. When compared to single vision lenses, Hal slowed progression by 0.80D and axial elongation by 0.35mm on average.

When children wore Hal lenses for more than 12 hours a day, every day, myopia control efficacy increased to 0.99D and 0.41mm axial length efficacy on average, compared to single vision lenses.